Pattern has announced $9 million in additional funding to accelerate the development and clinical validation of its Digital Culture^TM rapid bacterial identification and susceptibility testing (ID/AST) technology, a diagnostic project that is funded by CARB-X. The new funding is led by Illumina Ventures and OmniMed Capital.